BRAIN Biotech AG (BNN.DE)
EUR 3.77
(-3.58%)
EUR 3.77
(-3.58%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.65 Million EUR | 53.41% |
| 2022 | 3.03 Million EUR | 14.91% |
| 2021 | 2.64 Million EUR | -91.36% |
| 2020 | 30.59 Million EUR | 7.82% |
| 2019 | 28.37 Million EUR | 2.1% |
| 2018 | 27.79 Million EUR | 186.69% |
| 2017 | 9.69 Million EUR | 0.05% |
| 2016 | 9.68 Million EUR | -40.76% |
| 2015 | 16.35 Million EUR | 241.68% |
| 2014 | 4.78 Million EUR | 35.67% |
| 2013 | 3.52 Million EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 37.49 Million EUR | 0.0% |
| 2024 Q1 | - EUR | -100.0% |
| 2024 Q3 | - EUR | -100.0% |
| 2023 Q3 | - EUR | -100.0% |
| 2023 Q4 | 4.65 Million EUR | 0.0% |
| 2023 FY | 4.65 Million EUR | 53.41% |
| 2023 Q1 | - EUR | -100.0% |
| 2023 Q2 | 28.65 Million EUR | 0.0% |
| 2022 Q3 | - EUR | -100.0% |
| 2022 Q2 | 26.66 Million EUR | 0.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 FY | 3.03 Million EUR | 14.91% |
| 2022 Q4 | 3.03 Million EUR | 0.0% |
| 2021 FY | 2.64 Million EUR | -91.36% |
| 2021 Q2 | 26.96 Million EUR | 0.0% |
| 2021 Q3 | - EUR | -100.0% |
| 2021 Q4 | 2.64 Million EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2020 Q2 | 33.77 Million EUR | 0.0% |
| 2020 Q3 | - EUR | -100.0% |
| 2020 Q4 | 30.59 Million EUR | 0.0% |
| 2020 FY | 30.59 Million EUR | 7.82% |
| 2020 Q1 | - EUR | -100.0% |
| 2019 Q3 | - EUR | -100.0% |
| 2019 FY | 28.37 Million EUR | 2.1% |
| 2019 Q4 | 28.37 Million EUR | 0.0% |
| 2019 Q2 | 27.24 Million EUR | 0.0% |
| 2019 Q1 | - EUR | -100.0% |
| 2018 Q3 | - EUR | -100.0% |
| 2018 Q4 | 27.79 Million EUR | 0.0% |
| 2018 FY | 27.79 Million EUR | 186.69% |
| 2018 Q1 | - EUR | -100.0% |
| 2018 Q2 | 27.52 Million EUR | 0.0% |
| 2017 FY | 9.69 Million EUR | 0.05% |
| 2017 Q1 | - EUR | -100.0% |
| 2017 Q2 | 9.12 Million EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q4 | 9.69 Million EUR | 0.0% |
| 2016 FY | 9.68 Million EUR | -40.76% |
| 2016 Q4 | 9.68 Million EUR | 0.0% |
| 2016 Q2 | 9.52 Million EUR | 0.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 Q3 | - EUR | -100.0% |
| 2015 Q4 | 16.35 Million EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 FY | 16.35 Million EUR | 241.68% |
| 2014 FY | 4.78 Million EUR | 35.67% |
| 2013 FY | 3.52 Million EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| BioNTech SE | 219.1 Million EUR | 97.874% |
| CureVac N.V. | 41.85 Million EUR | 88.87% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | 99.325% |
| Biotest Aktiengesellschaft | 689.8 Million EUR | 99.325% |
| Formycon AG | 29.48 Million EUR | 84.199% |
| Heidelberg Pharma AG | 5.83 Million EUR | 20.105% |
| Medigene AG | 2.95 Million EUR | -57.932% |